Liver transplantation for hepatocellular carcinoma: recent advances in China.

Orthotopic liver transplantation is currently the best treatment option for selected patients with hepatocellular carcinoma (HCC). From 1980 to 2011, 8874 patients with HCC in China underwent liver transplantation. The organ donation classification criteria of China (China criteria), which are established by the Government of China, are divided into three parts: China criteria I, donation after brain death; China criteria II, donation after cardiac death and China criteria III, donation after dual brain-cardiac death. Data from the China Liver Transplant Registry(CLTR) System shows that patients within the Milan criteria have higher survival rates than those who are beyond these criteria. Based on CLTR data, altogether 416 patients received living-donor liver transplantation(LDLT) in China. Their 1-year and 3-year survival rates were significantly higher than those of the non-LDLT recipients. The most common early stage(<30 days after liver transplantation) complications include pleural effusion, diabetes, peritoneal effusion or abscess, postoperative infection, hypertension and intraperitoneal hemorrhage; while the most common late stage (≥ 30 days after liver transplantation) complications were diabetes, hypertension, biliary complications,postoperative infection, tacrolimus toxicity and chronic graft rejection. The incidence of vascular complication, which is the main reason for acute graft failure and re-transplantation, was 2.4%. Liver transplantation is an effective treatment for patients with HCC in China.
AuthorsTian Fei Lu, Xiang Wei Hua, Xiao Lan Cui, Qiang Xia
JournalJournal of digestive diseases (J Dig Dis) Vol. 15 Issue 2 Pg. 51-3 (Feb 2014) ISSN: 1751-2980 [Electronic] Australia
PMID24734307 (Publication Type: Journal Article)
  • Carcinoma, Hepatocellular (epidemiology, surgery)
  • China (epidemiology)
  • Female
  • Humans
  • Liver Neoplasms (surgery)
  • Liver Transplantation (adverse effects, methods, trends)
  • Living Donors
  • Male
  • Middle Aged
  • Registries

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: